Papillary lesions of the breast range from benign to atypical to malignant. Although papillomas without frank cancer are benign, their management remains controversial. When a core needle biopsy of a lesion yields a diagnosis of intraductal papilloma with atypia, excision is generally recommended to rule out a concurrent malignant neoplasm. For intraductal papillomas without atypia, however, recommendations for excision versus observation are variable. The aims of this study are to evaluate the rate of concurrent malignancies for intraductal papilloma diagnosed on core needle biopsy and to assess the long-term risk of developing cancer after the diagnosis of a papillary lesion. This single institution retrospective study analyzed 259 patients that were diagnosed with intraductal papilloma (IDP) by core needle biopsy from 1995 to 2010. Patients were grouped by initial diagnosis into three groups (papilloma without atypia, papilloma with atypia, and papilloma with atypical duct hyperplasia or atypical lobular hyperplasia (ADH/ALH) and followed up for long-term outcomes. After a core needle biopsy showing IDP with atypia or IDP + ADH/ALH, surgical excision yielded a diagnosis of concomitant invasive or ductal in situ cancer in greater that 30% of cases. For intraductal papilloma without atypia, the likelihood of cancer was much lower. Moreover, even with excision, the finding of intraductal papilloma with atypia carries a significant risk of developing cancer long-term, and such patients should be followed carefully and perhaps should be considered for chemoprevention.
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| INTRODUCTION
Intraductal papillomas (IDP) are lesions of the breast that occur in the ducts of the mammary glands as a result of epithelial and myoepithelial hyperplasia surrounding a fibrovascular stalk. 1 IDPs can pathologically range from benign, to atypical or malignant. 2 Their clinical presentation can also vary between spontaneous nipple discharge, detection on routine mammography or, infrequently, a palpable mass. 3, 4 Even though IDPs without frank cancer are generally considered to be benign, their management is controversial. When a core needle biopsy (CNBx) of a lesion yields a diagnosis of IDP with atypia, excision is generally recommended to rule out a concurrent malignant neoplasm. 5 For IDPs without atypia, however, recommendations for excision versus observation are variable. 6, 7 A clearer understanding of the likelihood of coincident invasive or in situ malignancy, as well as the long-term risk for cancer would be helpful in the management of these patients. If the risk of cancer is low, we can avoid unnecessary surgical procedures, the potential for complications, as well as the costs and loss of productivity. On the other hand, if observation of these lesions will lead to under-diagnosis of curable cancers, we may not be providing the most appropriate management. The aims of this study are to evaluate the rate of concurrent malignancies for IDP diagnosed on CNBx and to assess the long-term risk of developing cancer after the diagnosis of a papillary lesion. We hypothesized that IDPs without atypia do not require excision, because the risk of malignancy is low. Conversely, we hypothesized that IDPs with atypia should be excised because of a significant rate of concomitant malignancy. We also sought to analyze whether papillary lesions are an indicator of increased risk of developing breast cancer in the long-term.
| ME TH ODS
The Institutional Review Board of the Virginia Commonwealth University and the Massey Cancer Center approved this retrospective chart review without the need for patient consent. Patient data were de-identified and coded.
| Population
A total of 1495 patient records were drawn from the VCU Health System/Massey Cancer Center surgical pathology and breast-imaging records for women who underwent a biopsy between 1995 and 2010, using a keyword based search with words including "papilloma", and "papillary". All duplicated records were removed (N = 92).
The slides from the surgical pathology were not re-reviewed for this study. Anyone whose initial biopsy was not charted as a CNBx or 
| Data analysis
For any subject for whom a date had missing values for day and month, we imputed the mid-year day and month (July 2 of that year recorded F I G U R E 1 Flow diagram of the process through phases of diagnosis group assignment (that is exclusion and analysis)
The same three groups were then defined based on the "worst diagnosis" (defined as the highest grade pathology on either the CNBx or excision). The Kaplan-Meier method was used to estimate cancer-free survival for patients who underwent excision within these three groups, eliminating those that had a diagnosis of cancer on initial excision (N = 238). Additionally, the Kaplan-Meier method was also used to estimate cancer-free survival of three groups based only on the core biopsy diagnoses. Post hoc tests comparing the cancer-free survival of the three groups were performed using Holm's step down method. For the patients who had a diagnosis of breast cancer subsequent to the definitive biopsy, time was taken to be the time between diagnostic biopsy and diagnosis of breast cancer. For all other patients, time was taken to be the time between diagnostic biopsy and follow-up. Reported from each Kaplan-Meier curve was the probability of survival without cancer at 10 years.
For patients with CNBx diagnosis of IDP without atypia and who did not have an excisional biopsy, the Kaplan-Meier method was used to estimate cancer-free survival (N = 107). There were too few patients with atypia (2) or ADH/ALH (3) who did not undergo excision to make a similar analysis meaningful. For patients with IDP without atypia, we also compared the cancer-free survival of those who had an excision versus those who were observed. The probability of remaining cancer free for these patients was estimated at 5 years and 10 years.
All statistical tests were performed at an alpha level of 0.05, unless otherwise specified. The R programming environment was used for all analysis and plots.
3 | RESULTS Table 1 shows the demographic and clinical factors for each of the three CNBx diagnoses. The changes in diagnoses between core biopsy and definitive excision can be seen in Table 2 . Excisional biopsies were performed on 147 patients. Tables S1-S3 . There were no statistically significant differences in these factors found between those who had cancer on excision and those that did not have cancer on excision for any of the three CNBx diagnoses.
3.1 | Long-term outcomes Table 3 shows the follow-up characteristics for patients by their
CNBx diagnoses. Figure 2 shows Kaplan-Meier curves of cancer-free survival for patients without a diagnosis of cancer at initial excision.
The three diagnostic groups are defined using the worst diagnosis (either at core biopsy or excision). It is concluded that, at an alpha level of 0.05, there is a statistically significant difference in the cancer-free survival curves (P = .0112). Using Holm's step down method, a statistically significant difference in cancer-free survival was found between those with a worst diagnosis of IDP without atypia versus IDP with atypia (P = .0056). When adjusting the alpha level to account for the multiple two-group comparisons performed, there were not any significant differences between IDP without atypia and IDP with ADH/ALH (P = .044) or between IDP with Atypia and IDP with ADH/ALH (P = .688). Using the survival curves, the probability of remaining cancer free in either breast at 10 years is shown in Table 4 Additionally, when the three diagnostic groups are defined using only the core biopsy diagnoses, it is concluded that at an alpha level of 0.05 there is a significant difference in the survival curves (P < .001, Figure 3 ). Post hoc tests were performed using Holm's step down method. A significant difference in cancer-free survival was found between those with a core biopsy diagnosis of IDP without atypia and IDP with atypia (P < .001) and between those with a core biopsy diagnosis of IDP without atypia and IDP with ADH/ALH (P < .001). When adjusting the alpha level to account for the multiple two-group comparisons performed, there was not a significant difference between those with a core biopsy diagnosis of IDP with atypia and IDP with ADH/ALH (P = .981). Using the survival curves, the probability of remaining cancer free in either breast at 10 years is shown in Table 5 with the management of papillary lesions without atypia. 5, 8, 9 Results have varied in the relationship between papillary lesions without atypia and cancer, with upgrade rates to a cancer diagnosis ranging from 2% to 33%. 8, 9 Researchers have intensively looked into the cause of this discrepancy. Glenn et al 10 looked into whether the size of the papilloma was a good indication of the need for surgery and found that there was no size threshold below which it is safe to say that an excision is not necessary. Lesion size was not consistently available in our dataset, so analysis according to size was not feasi- including small cohort sizes, not specifically separating out IDP with atypia from those without, or just genuine differences. 2, 9 Our study looked at a cohort of 259 patients who were diagnosed as having a papillary lesion on CNbx without any associated invasive or in situ malignancy. By separating these patients into three groups (IDP without atypia, IDP with atypia, and IDP with ADH/ALH), we were able to assess accurately the significance of F I G U R E 3 Cancer free survival curves for the three groups based on only the core biopsy diagnoses T A B L E 5 The probability of remaining cancer-free in either breast at 10 years using only the core biopsy diagnosis Our study had some limitations. Firstly, papilloma is a rare diagnosis and this study is a single breast center study; therefore, it is difficult to establish a large cohort of patients. However, this study represents one of the largest cohorts of its kind published to date.
Number of patients
Secondly, this is a retrospective study, but practice guidelines were relatively standardized and consistent throughout the study period allowing for homogeneity in decision-making among our cohort.
Third, while the follow-up time is shorter than desired, our study does describe a cohort with longer follow-up than most previous studies of papillary breast lesions.
In summary, after a CNBx showing IDP with atypia or IDP + ADH/ALH, surgical excision is clearly justified, based on a >30% risk of concomitant invasive or in situ cancer. For IP without atypia, however, the likelihood of cancer either concomitantly or in the next 5 years is much lower (4.2%). Even with excision, the finding of IDP, particularly if associated with findings of atypia, appears to be a marker for a moderately high risk of developing cancer longterm, and such patients should be followed carefully and perhaps should be considered for chemoprevention.
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